Stray Dog

Hims & Hers: FTC suit widens to seven states

  • Bad news: The FTC suit grew from two states to seven, with state consumer-protection claims added, tilting settlement leverage towards plaintiffs.
  • Mixed: Peptides+ launches at the end of November, but the chief financial officer says peptide revenue will be immaterial this year.
  • Bad news: Branded weight-loss drugs have cut gross margin from 74% to 57%, and peptides cannot offset that soon.
Read the full notes

Thesis maintained, with a warning flag ⚠️. The regulatory thread has worsened another notch: the plaintiffs in the Federal Trade Commission (FTC) suit have grown from two states to seven (Arizona, Florida, Nebraska, Ohio and Wisconsin are new), and state consumer-protection claims have been added, tilting settlement leverage further towards the plaintiffs.

Read more

The real risk is not the $62.5 million accrued for a fine. It is that an injunction restricting the return of health data to advertising platforms would hurt acquisition efficiency when marketing resumes for the Q1 weight-loss season. The peptides line, Peptides+ (NAD+, sermorelin, glutathione and B12), launches at the end of November, while BPC-157 and TB-500 are on hold to avoid regulatory risk. The chief financial officer said clearly that peptide revenue will be immaterial this year. The direction is right (longevity and a growing store of health data), but in the short term it cannot offset the way branded weight-loss drugs have cut gross margin from 74% to 57%.

Brief ID

2026-11-11-hims-ftc-7states-peptides-plus-launch

Key evidence

  • On 10 Nov the FTC filed an amended complaint in the federal court for the Northern District of California, approved by a 2-0 vote of the commission
  • Five states join as co-plaintiffs: Arizona, Florida, Nebraska, Ohio and Wisconsin
  • With Utah and California from the original 29 Jul suit, that makes seven states
  • State consumer-protection claims are added to the existing charges under the FTC Act and the Restore Online Shoppers' Confidence Act
  • The allegations are unchanged: (1) health information was passed to advertising platforms such as Meta and Snap as customer lists and website tracking events; (2) customers were charged for medication after the intake form but before seeing a doctor, subscriptions renewed automatically, and the cancel button was buried several pages deep
  • The company says these are follow-on allegations and that it will defend itself vigorously
Show 10 more
  • On 30 Oct the judge indicated that a dismissal of the suit is unlikely
  • HIMS has accrued about $62.5 million for a fine
  • Peptides+ launches at the end of November, starting with NAD+, sermorelin, glutathione and vitamin B12, with blood testing and ongoing clinical follow-up
  • BPC-157, TB-500 and similar products will be added when the regulatory environment allows, and the company will make them in the US
  • Chief financial officer Okupe said clearly that peptide revenue will be immaterial this year
  • The first four are not among the six core products on the 30 Oct Federal Register enforcement-discretion list
  • The 30 Oct Federal Register policy is enforcement discretion, not approval. Comments close on 13 Nov, and it can be withdrawn
  • Branded weight-loss drugs have cut gross margin from 74% to 57%
  • The company has deliberately scaled back marketing in Q4 and plans to resume it for the Q1 weight-loss season
  • No new SEC EDGAR filings since the 10-Q and two 8-Ks of 9 Nov

Reporter

Our research team

Catalysts to watch

  • The terms of any FTC settlement (whether an injunction restricts the return of health data to advertising platforms)
  • Acquisition efficiency when marketing resumes for the Q1 weight-loss season
  • The launch date for BPC-157 and TB-500 (depends on the final regulation after 13 Nov)
  • Whether Q4 and Q1 results separately disclose peptide or longevity subscriber numbers
  • Whether more states join the suit

Risks

  • A wider group of seven plaintiff states tilts settlement leverage towards the plaintiffs
  • If the injunction restricts returning health data to advertising platforms, acquisition efficiency will suffer directly
  • The gross margin has been squeezed structurally from 74% to 57%, and peptides cannot offset it in the short term
  • The peptides strategy is conservative: avoiding the enforcement-discretion risk on BPC-157 and TB-500 means no high-profile SKU for now
  • The policy can be withdrawn, so the long-term rollout of peptides remains uncertain

Sources 6

  1. Federal Trade Commission press release (10 Nov)
  2. Reuters (9 Nov, 10 Nov)
  3. MLex
  4. HIMS Q3 call minutes
  5. Reuters interviews with chief executive Dudum and chief financial officer Okupe
  6. SEC EDGAR